10-Q: Regenerex Pharma Reports Q2 2024 Results: Losses Narrow Amidst Development Efforts

Regenerex Pharma's Q2 2024 results show a decreased net loss compared to the same period last year, as the company continues to develop and market wound care products.

Summary

• Regenerex Pharma, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2024.
• The company is focused on developing and marketing wound care healing products.
• For the six months ended September 30, 2024, the company reported a net loss of $802,132, compared to a net loss of $2,987,024 for the same period in 2023.
• The decrease in net loss is attributed to reduced research and development expenses, lower stock-based compensation, and decreased administrative expenses.
• The company has no revenue for the six months ended September 30, 2024 and 2023.
• The company's primary sources of liquidity have been notes payable, which are not sufficient prospectively.
• Management plans to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability.
• The company is developing managed care agreements with southeastern states to manage their Medicaid wound care patients.
• The company is also negotiating with several distributors in various Middle Eastern countries to provide the company's products.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its net loss, it still faces significant challenges, including a lack of revenue, reliance on debt financing, and uncertainty about its ability to continue as a going concern. The company is actively pursuing new business opportunities, but its future success is not guaranteed.

Positives

• The net loss decreased significantly from $2,987,024 in 2023 to $802,132 in 2024.
• The company is actively pursuing new business opportunities, including managed care agreements and international distribution.
• The company has proprietary wound care formulations and has entered into an agreement to lease a plant and equipment in Tennessee.
• The company has three technologies for different types of wound conditions.

Negatives

• The company has no revenue for the six months ended September 30, 2024 and 2023.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company requires significant cash to launch its business and reduce its payable.
• The company's primary sources of liquidity and capital resources have been notes payable, which are not sufficient prospectively.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of losses and limited capital resources.
• The company's success depends on its ability to raise additional capital and achieve profitability.
• The company faces risks related to the impacts of COVID-19 or other future pandemics on its business.
• The company's success depends on its ability to develop and market its wound care products effectively.
• The company is subject to risks and uncertainties inherent in its statements regarding the impacts of COVID-19, or other future pandemics on its business, results of operations, financial position, and cash flows.

Future Outlook

Management expects to launch its sales initiative during the Company's third or fourth quarter of the year ending March 31, 2025 and is actively seeking capital to enable the Company to add new products and/or services to ultimately achieve profitability.

Management Comments

• Management plans to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability.
• Management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital.

Industry Context

The company operates in the wound care market, which is characterized by a growing prevalence of chronic wounds and increasing cost pressures in the healthcare system.

Comparison to Industry Standards

• The document mentions that Regenerex System has been shown in many clinical trials to successfully close up to 95% of non-responding chronic wounds within 90 days.
• The document claims that competitive clinical trials indicated there isn't another System that has the ability to close chronic wounds at these levels and speed.
• The document claims that QBx technology is the most efficacious, and clinically proven Chronic wound Care product in the world.

Related Party Transactions

• The Company purchased assets from the Company's current Chief Executive Officer (CEO) and Secretary/Treasurer.
• The Company, has entered into an agreement with Woundcare Labs, LLC., a party related to the CFO and CEO of the Company, to lease a plant and to lease equipment in Tennessee.
• During the six-month period ended September 30, 2024 and 2023, the Company's Chief Financial Officer (CFO) and the Company's Chief Executive Officer (CEO) advanced the Company monies for operating expenses in the net amount of $0 and $2,437, respectively.
• During the six-month period ended September 30, 2024 and 2023, the Company's CFO and the Company's CEO advanced the Company monies for operating expenses in the amount of $131,860 and $0, respectively.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital through equity offerings.
• Employees' job security is uncertain due to the company's financial difficulties.
• Customers may benefit from the company's wound care products if they are successfully developed and marketed.
• Suppliers and creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company expects to launch its sales initiative during the third or fourth quarter of the year ending March 31, 2025.
• The company will continue to develop managed care agreements with southeastern states.
• The company will continue to negotiate with several distributors in various Middle Eastern countries.
• Management will continue to seek guidance from third-party experts and consultants to gain a thorough understanding of these transactions.
• Management will continue to monitor and evaluate the designation, implementation and effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implement additional enhancements or improvements, as necessary.

Key Dates

Keywords

wound care, Regenerex Pharma, financial results, 10-Q, intellectual property, Medicaid, net loss, going concern, capital resources, notes payable